In the past year, we have witnessed a major shift in the political landscape when it comes to medical marijuana and the public’s understanding of cannabidiol. Most recently, leaders in the Senate on both sides of the political aisle are demanding the federal government take steps to further advance clinical cannabis research.
On July 9, Senator Elizabeth Warren (D-MA), along with Senators Cory Booker (D-NJ), Barbara Boxer (D-CA), Kirsten Gillibrand (D-NY), Edward Markey (D-MA), Jeff Merkley (D-OR), Barbara Mikulski (D-MD), and Ron Wyden (D-OR), sent a formal letter to representatives of the US Department of Health and Human Services (HHS), the Office of National Drug Control Policy (ONDCP), and the Drug Enforcement Administration (DEA) urging them to take efforts to better facilitate “large scale clinical trials” in regard to the use of medical marijuana in states that have legalized it.
The letters states: “HHS has tools to collect data, conduct surveillance, and perform large scale clinical trials while states continue to focus on implementation. HHS has the capacity to facilitate interstate communication in order to derive a more accurate picture of medical marijuana use and treatments across the country. It is time for the federal government to pick up these tools and use them.” […]